

4

RECEIVED

MAR 06 2002

TECH. CENTER 160012900



DATE: February 26, 2002 SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6696.US.02

SERIAL NO.

09/833,914

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT(S)

M. R. Schrimpf, et al.

FILING DATE

April 12, 2001

GROUP

1615 1624

(Use several sheets if necessary)

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS


EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
BC	A1	5,071,999	12/10/91	Schenke et al.	548	453	
BC	A2	5,382,584	01/17/95	Balasubramanian	514	215	
BC	A3	5,472,958	12/5/95	Gunn et al.	514	210	
BC	A4	5,478,939	12/26/95	Trybulski et al.	544	336	
BC	A5	5,773,912	06/30/98	Saeki et al.	310	326	
BC	A6	5,914,328	06/22/99	Lin et al.	514	252	
BC	A7	5,948,793	09/7/99	Abreo et al.	514	318	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
BC	B1	0 324 543	19.07.89	EP	—	—	YES	NO
BC	B2	0 345 808	11.01.95	EP	—	—		
BC	B3	0 400 661	05.12.90	EP	—	—		
BC	B4	0 603 887	26.09.94	EP	—	—		
BC	B5	94/08922	28.04.94	WO	—	—		
BC	B6	95/23152	31.08.95	WO	—	—		
BC	B7	96/31475	10.10.96	WO	—	—		
BC	B8	97/17961	22.05.97	WO	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

BC	C1	Americ et al., "Cholingeric channel modulators as a novel therapeutic strategy for alzheimer's disease," Exp. Opin. Invest. Drugs 5(1):79-100 (1996)
BC	C2	Americ, et al., "Neuronal Nicotinic Acetylcholine Receptors," Psychopharmacology: The fourth Generation of Progress 95-109 (1995)
BC	C3	Barlocco et al., J. Med. Chem. 41:674-681 (1998)



RECEIVED
MAR 06 2002

TECH CENT
600/2900

BC	C4	Benowitz, et al., "Pharmacokinetics, metabolism, and pharmacodynamics of nicotine," Nicotine Psychopharmacology 112-157 (1990)
BC	C5	Berge, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences 66(1):1-19 (1976)
BC	C6	Brehm et al., "Glycine antagonists, synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions," J. Med. Chem. 269:224-229 (1986)
BC	C7	Chem Pharm Bull. 6:408-411 (1958)
BC	C8	Cherny, "Opioid Analgesics," Drug 51(5):713-737 (1996)
BC	C9	Cope et al., "Syntheses of D-and L-2,6-diheterobicyclo [3.3.0]octanes," JACS 78:5916-5920 (1956)
BC	C10	Corey, et al., "A synthetic method for formyl-ethyl conversion (RCHO-RC=CH or CR)," Tetrahedron Letters 36:3769-3772 (1972)
BC	C11	Davidson, et al., "Cholinergic Agonists in alzheimer's Disease Patients," Current Research in Alzheimer Therapy 333-336 (1988)
BC	C12	Dormoy, "Synthese Industrielle en serie ellipticine," Tetrahedron 49(14):2885-2914 (1993)
BC	C13	Dray et al., "New pharmacological strategies for pain relief," Annu. Rev. Pharmacol. Toxicol 36:253-80 (1996)
BC	C14	Dray, et al., Trends in Pharmacol. Sci. 15:190-197 (1994)
BC	C15	Gribble, et al., "Regioselective ortho lithiation of halopyridines," Tetrahedron letters 21:4137-4140 (1980)
BC	C16	Hands, et al., "A convenient method for the preparation of 5-,6 and 7-azaindoles and their derivatives," Synthesis 877-882 (1996)
BC	C17	IUPAC, Pure and Applied Chemistry 45:13-30, 1976
BC	C18	Jacquet et al., Tetrahedron Letters 32(12):1565-1568 (1991)
BC	C19	Knight et al., "6-Hydroxypiperidinecarboxylates: additions to the chiral pool from bakers' yeast reduction of beta-ketopiperidinecarboxylates," J. Chem Soc. Perkins Trans. 1:3673-3683 (1998)
BC	C20	Korczyn, "Parkinson's Disease" Psychopharmacology: The Fourth Generation of Progress 126:1479-1484, 1995
BC	C21	Lazar, et al., "Saturated heterocycles, Part 172. Synthesis of 2,6-disubstituted-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine derivatives," J. Heterocyclic Chem. 27:1885-1892 (1990)
BC	C22	Linstrom, "Nicotinic Acetylcholine Receptors in Health and disease," Molecular Neurobiology 15:193-222 (1997)
BC	C23	Lloyd et al, "The potential of subype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents," Life Sciences 62(17/18):1601-1606 (1998)
BC	C24	Numata, et al., "General synthetic method for naphthyridines and their n-oxides containing isoquinolinic nitrogen," Synthesis 2:306-311 (1999)
BC	C25	Organic Mass Spectrometry 19(9):459-450 (1984)
BC	C26	Padwa, et al., Organic Synthesis 67:133-140 (1988)
BC	C27	Pabreza et al., Molecular Pharmacology 39:9-12 (1990)
BC	C28	Pascoe et al. Prescott, Methods in Cell Biology XIV:33-71 (1976)
BC	C29	Reimschuessel, et al., "Studies on new derivatives of caprolactam," Journal of Organic Chemistry 34(4):959-963 (1969)
BC	C30	Ronn, et al., "Palladium(II)-Catalyzed Cyclization Using Molecular Oxygen as reoxidant," Tetrahedron Letters 36(42):7749-7752 (1995)
BC	C31	Roth, et al, "Biochemical Pharmacology of Midbrain dopamine Neurons," Psychopharmacology: The Fourth Generation of Progress 227-243 (1995)

RECEIVED

MAR 06 2002

TECH CENTER 1600/2900



BC	C32	Salin-Pascual, et al., "Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression," J. Clin. Psychiatry 57:387-389 (1996)
BC	C33	Clayton, et al., "A total synthesis of (±)-Epibatidine," Tetrahedron Letters 36(46):7493-7496 (1993)
BC	C34	Sirisoma, et al., "Alpha-Iodocycloalkenones: synthesis of (±)-Epibatidine,," Tetrahedron Letters 39:2059-2062 (1998)
BC	C35	Wagaw, et al., "The synthesis of aminopyridines: A method employing palladium-catalyzed carbon-nitrogen bond formation," J. Org. Chem. 61:7240-4241 (1996)
BC	C36	Williams et al., "Beyond the tobacco debate: dissecting out the therapeutic potential of nicotine," Exp. Opin. Invest. Drugs 5(8):1035-1045 (1996)
BC	C37	Williams, et al., J. Med. Chem. 42(9):1481-1500 (1999)
BC	C38	Wittenberger, et al., "Dialkyltin Oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazoles," J. Org. Chem. 58:4139-4141 (1993)
BC	C39	Ghelardini et al., "Antinociceptive profile of the new nicotinic agonists DBO-83," Drug Development Research 40:251-258 (1997)

EXAMINER

Brenda Coleman

DATE CONSIDERED

Dec. 12, 2002

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)